Circulating Tumor Cells as Predictors of Response and Failure in Breast Cancer Patients Treated with Preoperative Chemotherapy

Boutrus, Rimoun; Raad, R.F. Abi; Kuter, Irene; Ancukiewicz, Marek; Roberts, Lisa; Solomon, Natalie; Ngo, Taylor; Borick, Heather; Ryan, Paula D.; Moy, Beverly; Gadd, Michele A.; Chien, Jo; Younger, Jerry; Smith, Barbara L.; Taghian, Alphonse G.; Harris, Lyndsay N.

doi:10.5301/jbm.2012.9580

Cited by 6 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

show abstract

“…Finally, 50 studies were eligible for meta-analysis (Fig. 1)4591112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657.…”

Section: Resultsmentioning

confidence: 99%

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Yan

Cui

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Pierga et al (95) found a significant correlation between CTC detection before NT and reduced DFS, but no correlation between the persistence of CTCs post-NT and tumor response. Boutrus et al (96) also found that CTC presence predicted local and distant relapse, but did not correlate with primary tumor volume reduction. Similarly, Riethdorf et al (68) showed that CTC detection before NT did not correlate with tumor response to treatment, nor did CTC changes necessarily mirror treatment response.…”

Section: Monitoring Treatment – Clinical Utilitymentioning

confidence: 97%

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelialâ€“Mesenchymal Plasticity

et al. 2015

View full text Add to dashboard Cite

There is increasing interest in circulating tumor cells (CTCs) due to their purported role in breast cancer metastasis, and their potential as a “liquid biopsy” tool in breast cancer diagnosis and management. There are, however, questions with regards to the reliability and consistency of CTC detection and to the relationship between CTCs and prognosis, which is limiting their clinical utility. There is increasing acceptance that the ability of CTCs to alter from an epithelial to mesenchymal phenotype plays an important role in determining the metastatic potential of these cells. This review examines the phenotypic and genetic variation, which has been reported within CTC populations. Importantly, we discuss how the detection and characterization of CTCs provides additional and often differing information from that obtained from the primary tumor, and how this may be utilized in determining prognosis and treatment options. It has been shown for example that hormone receptor status often differs between the primary tumor and CTCs, which may help to explain failure of endocrine treatment. We examine how CTC status may introduce alternative treatment options and also how they may be used to monitor treatment. Finally, we discuss the most interesting current clinical trials involving CTC analysis and note further research that is required before the breast cancer “liquid biopsy” can be realized.

show abstract

“…Indeed, a O33% higher number of CTC, measured after 3-5 weeks of treatment, was associated with poorer PFS and OS (respective HR, 23.1 and 18.9) compared with no increase (Khan et al 2012). Whether serial CTC determinations could be relevant for NET follow-up and a potential surrogate of therapeutic response requires further investigation in specific clinical trials, as shown for other malignancies (Matsusaka et al 2010, Danila et al 2011, Hiltermann et al 2012, Boutrus et al 2013. However, the main limitations of using CTC in routine practice are the limited availability and non-standardization of their measurement technique.…”

Section: Biological Markers Tumor Progression and Therapeutic Respomentioning

confidence: 99%

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art

Mestier¹,

Dromain²,

d’Assignies³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Well-differentiated neuroendocrine tumors (NETs) are a group of heterogeneous rare tumors. They are often slow-growing and patients can have very long survival, even at the metastatic stage. The evaluation of tumor progression and therapeutic responses is currently based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST) criteria. As for other malignancies, RECIST criteria are being reexamined for NETs in the era of targeted therapies because tumor response to targeted therapies is rarely associated with shrinkage, as opposed to prolonged progression-free survival. Therefore, size-based criteria no longer seem to be suitable to the assessment of NET progression and therapeutic responses, especially considering targeted therapies. New imaging criteria, combining morphological and functional techniques, have proven relevant for other malignancies treated with targeted therapies. To date, such studies have rarely been conducted on NETs. Moreover, optimizing the management of NET patients also requires considering clinical, biological, and pathological aspects of tumor evolution. Our objectives herein were to comprehensively review current knowledge on the assessment of tumor progression and early prediction of therapeutic responses and to broaden the outlook on well-differentiated NETs, in the era of targeted therapies.

show abstract

Circulating Tumor Cells as Predictors of Response and Failure in Breast Cancer Patients Treated with Preoperative Chemotherapy

Abstract: CTCs can be used as predictors of relapse after definitive treatment of locally advanced breast cancer; however, CTCs detection in peripheral blood during the course of PC does not implicate a particular pattern of response to treatment.

Cited by 6 publications

References 30 publications

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis

Clinical Implications of Circulating Tumor Cells of Breast Cancer Patients: Role of Epithelialâ€“Mesenchymal Plasticity

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art

Contact Info

Product

Resources

About